After an inspection at the Pithampur plant, the USFDA issued a warning letter stating that the company’s methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to good manufacturing practices, and that its drug products are adulterated.
| Subscribe To Our Free Newsletter |
